PG115 COSTS OF CROHN'S DISEASE WITHIN THE GERMAN STATUTORY HEALTH INSURANCE  by Prenzler, A et al.
CONCLUSIONS: In chronic HBV infected patients, tenofovir is a
cost-effective or even a dominant (lower cost and (higher efﬁcacy)
strategy in comparison to the rest of available therapies for CHB
in Spain.
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OBJECTIVES: Post-operative ﬁstulas are a serious complication
of gastrointestinal tract surgery that can highly increase the
length of hospitalization stays. Somatostatin, such as lanreotide,
are being used to reduce time elapsed for ﬁstula closure. In
France, non expensive drugs are directly ﬁnanced through DRG
tariff. In this context, the objective of the study was to evaluate,
from a public hospital perspective, whether the additional costs
associated with lanreotide treatment could be counter-balanced
by its impact on health resources consumption and length of stay
compared to conventional care management and natural soma-
tostatin. METHODS: We assumed that the treatment duration
corresponds to the time required for ﬁstula closure and data
used were based on published clinical trials ﬁndings. Hospital
stays were identiﬁed from the French national hospital database
(PMSI) and costs of stays were determined through the French
national hospital costs database (ENC). Daily average cost of
stay was estimated considering both, length of stay, ﬁx and
variable costs within the ENC and was weighed by the number of
stays in each identiﬁed DRG. RESULTS: The analysis was based
on 2193 hospitalizations representing 74% of the stays with a
ﬁstula diagnosis. The average daily cost of stay was evaluated to
€170. Based on the clinical data available, the time for ﬁstula
closing was comparable for both drug treatments (12 days for
lanreotide and natural somatostatine) and, 18 days for the con-
ventional treatment. Thus, the total costs of stay including the
cost of drug were of €2929 for the lanreotide, €7747 for the
natural somatostatine and of €2981 for the conventional treat-
ment. CONCLUSIONS: The decreased ﬁstula closing time
associated with lanreotide treatment can potentially lead to a
reduction of the hospitalization length of stay which can com-
pensate the overcost of the drug.
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OBJECTIVES: To assess if acid related diseases are better
managed by empiric treatment or by a diagnostic approach.
METHODS: We analyzed the outcome of 182 patients with
dyspepsia and/or gastro-oesophageal reﬂux disease (GERD) in
primary care, over a period of 12 months, in the Campania
region (southern Italy). Patients were divided in two groups:
therapeutic group, if patients received pharmacological treat-
ment since the beginning, and diagnostic group, if underwent a
diagnostic approach. After 12 months the direct management
costs (consultations, diagnostic procedures, drugs) were calcu-
lated for both groups using National Health Service prospective
(expressed in Euro 2005). We analyzed the diagnostic procedures
deﬁned as “not useful”, procedures that did not provide addi-
tional information to help us decide on therapy changes, whether
the prescription had been prescribed only on the basis of the
symptoms (therapeutic group) or it had only been hypothesized
before the diagnostic approach (diagnostic group). RESULTS:
Ninety-eight patients were in therapeutic group (median age 49;
Males 53%) and 84 in diagnostic group (median age 50; Males
52%). For patients in the diagnostic group there were higher
management costs than for other patients (268 vs €156/year on
average). Diagnostic procedures did not modify the prescribed or
hypothesized therapy and clinical management in 75% (21/28)
of patients with GERD, 52% (26/50) with dyspepsia and 58%
(15/26) with both GERD and dyspepsia. Based on the estimated
prevalence of clinically relevant acid related diseases in Campa-
nia, the cost/year of “not useful” diagnostic procedures could
be of about 2.64, 4.16 and 10.73 million euros for GERD,
dyspepsia and dyspepsia-GERD, respectively. CONCLUSIONS:
Although the concept of “not useful” diagnostic procedure is
debatable, the results of this analysis further suggest to address
more attention to the improvement of education for disease
management with the aim to contain health care costs.
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OBJECTIVES: Data concerning treatment reality in patients
with Crohn’s disease (CD) are limited in Germany. Aim of this
cross-sectional study was to collect resource use data due to CD
and quantify these from the perspective of the Statutory Health
Insurance in Germany. METHODS: Between March 2006 and
July 2007 patients from 24 ambulatory gastroenterological
specialist practices and 2 hospitals were enrolled in an
internet-based online database. Based on the collected data, the
outpatient and inpatient visits, all incurred outpatient procedures
as well as medication usage were determined and evaluated from
the perspective of the Statutory Health Insurance. The year 2007
was selected as the price year. Sensitivity analyses were con-
ducted. RESULTS: Data from 511 CD-patients were collected,
with 37 % being male. Patients were on average 41 years old.
According to the calculations, an average CD-patient in
Germany causes costs of €3799 per year from the perspective of
the Statutory Health Insurance. The cost of €235 (6%) resulted
from outpatient specialists visits due to gastroenterological and
extra intestinal problems and €211 (6%) are due to outpatient
procedures, e.g. colonoscopies. The cost of €774 (20%) resulted
from inpatient care. The total of €2579 (68%) are medication
costs; 58% of these costs are due to TNF-alpha-inhibiting
medications. The costs increase with the severity of the disease.
A patient with an active disease (CDAI > 220) causes average
annual costs of €5377 (inpatient: €1075; medication: €3875)
being signiﬁcantly higher in comparison to patients in remission
(CDAI < 150) with €3116 (inpatient: €645; medication: €2070).
The results are robust. CONCLUSIONS: This is the ﬁrst study to
calculate costs due to CD from the perspective of the Statutory
Health Insurance in Germany. To illustrate the costs from the
societal perspective, indirect costs need to be included in the
calculation in future studies.
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